Get the Daily Brief
Latest Biotech News
AI-Accelerated RNA Therapeutics Development Gains Momentum
Cutting-edge artificial intelligence techniques are transforming RNA-based drug discovery and delivery. MIT researchers introduced a machine-learning model named COMET that accelerates the design...
CSL Restructures with Vaccine Spin-off and Workforce Cuts
Australian pharmaceutical giant CSL announced a strategic overhaul including spinning off its vaccine subsidiary, Seqirus, into a standalone entity and cutting up to 15% of its workforce. The...
Novo Nordisk Expands Wegovy Approval to Fatty Liver Disease
Novo Nordisk’s blockbuster GLP-1 agonist, Wegovy (semaglutide), gained accelerated FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH), representing the first GLP-1...
Viking Therapeutics Oral Obesity Pill Faces Investor Scrutiny
Viking Therapeutics reported positive Phase 2 results for VK-2735, an oral dual GLP-1/GIP receptor agonist showing up to 12.2% weight loss after 13 weeks. However, significant gastrointestinal...
Stealth BioTherapeutics Resubmits FDA Application for Rare Disease
Stealth BioTherapeutics resubmitted its drug candidate for Barth syndrome to the FDA after an earlier rejection citing insufficient efficacy evidence. The company is pursuing regulatory engagement...
Anocca Raises $46 Million to Fund Pancreatic Cancer T-Cell Therapy Trial
Swedish biotech Anocca secured $46 million in financing to advance the clinical development of VIDAR-1, a first-in-Europe nonviral genome-edited T-cell receptor (TCR) therapy targeting mutant KRAS...
New Structural Insights Across Oncology and Immunology Target Identification
Recent studies Illuminate mechanisms underpinning cancer and immune responses. Research from Rockefeller University identified a mitochondrial antioxidant pivotal to breast cancer metastasis,...
AI and Digital Tools Enhance Mental Health and Patient Monitoring
Innovative AI-driven approaches are advancing mental health care and remote patient management. A smartphone-delivered digital therapeutic demonstrated a 50% reduction in repeated suicide attempts...
Advances in Gene and Cell Therapy: Regulatory and Development Highlights
Recent advancements mark critical progress in gene and cell therapy. Kriya Therapeutics raised $313 million to fuel development of a diverse pipeline including neurology and ophthalmology...
Breakthrough in Large-Scale Single-Cell Arabidopsis Life Cycle Mapping
Researchers have successfully created a comprehensive single-cell, spatial transcriptomic atlas of the Arabidopsis thaliana life cycle. By using advanced spatial transcriptomics, this work maps...
Viking Therapeutics’ Oral Obesity Drug Drives Weight Loss but With High Discontinuation
Viking Therapeutics reported encouraging Phase 2 results for its oral obesity drug candidate VK-2735, showing statistically significant weight reductions of up to 12.2% after 13 weeks. However,...
CSL to Spin Off Seqirus Vaccine Unit and Implement Workforce Cuts
Australian drugmaker CSL announced a major restructuring plan involving up to 15% workforce reductions and the spin-off of its vaccine subsidiary Seqirus into a standalone public company. The move...
AI-Driven Collaboration to Advance Proximity-Based Therapeutics in Oncology and Immunology
VantAI, an AI firm specializing in programmable protein interactions, has entered a $1 billion+ partnership with clinical-stage biotech Halda Therapeutics. The collaboration leverages VantAI's...
FDA Rejects PTC's Friedreich’s Ataxia Drug, Requests Additional Trial
The FDA issued a complete response letter denying approval for PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient evidence of efficacy. The regulatory agency requested an...
Novo Nordisk’s Wegovy Gains FDA Approval for Fatty Liver Disease (MASH)
Novo Nordisk’s GLP-1 agonist Wegovy received FDA accelerated approval as the first drug indicated for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver...
Anocca Secures $46 Million for TCR T-Cell Therapy Targeting Pancreatic Cancer
Swedish biotech Anocca AB raised approximately $46 million (SEK 440 million) to advance its CRISPR-edited T-cell receptor (TCR) therapy, VIDAR-1, in Phase I clinical trials for pancreatic ductal...
Skyhawk Therapeutics Teams with Merck KGaA on Up to $2 Billion RNA-Targeted Neurology Pact
Skyhawk Therapeutics entered a collaborative agreement with Merck KGaA focused on discovering small-molecule RNA splicing modulators for neurological diseases. The deal, valued up to $2 billion,...
Groundbreaking Lab-Grown Human Spinal Cord Stem Cells Poised for First Human Transplant
Israeli researchers at Tel Aviv University successfully bioengineered human spinal cord stem cells in the laboratory, demonstrating unprecedented success in animal models. The technology,...
Novo Nordisk’s Wegovy Expands MASH Indication: FDA Accelerates Approval
Novo Nordisk’s popular GLP-1 drug Wegovy has secured accelerated FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), addressing a condition affecting an estimated 22 million...
Skyhawk Therapeutics Scores $2B Neurology RNA Deal with Merck KGaA
Skyhawk Therapeutics has entered a substantial collaboration with Merck KGaA, targeting neurological diseases through RNA splicing modulation with an agreement worth up to $2 billion. The...